Quizartinib (AC220)

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 1/2.

Price Stock Quantity  
In DMSO USD 353 In stock
USD 210 In stock
USD 370 In stock
USD 970 In stock
USD 2470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Quizartinib (AC220) Chemical Structure

Quizartinib (AC220) Chemical Structure
Molecular Weight: 560.67

Validation & Quality Control

Customer Reviews(1)

Quality Control & MSDS

Related Compound Libraries

Quizartinib (AC220) is available in the following compound libraries:

FLT3 inhibitors with Unique Features

Product Information

  • Compare FLT3 Inhibitors
    Compare FLT3 Inhibitors
  • Research Area

Product Description

Biological Activity

Description Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 1/2.
Targets Flt3ITD Flt3wt
IC50 1.1 nM [1] 4.2 nM [1]
In vitro AC220, a unique, potent and selective inhibitor of FLT3, has high affinity for FLT3 with a Kd value of 1.6 nM. AC220 inhibits the autophosphorylation of FLT3 in the human leukemia cell lines MV4-11 which harbor a homozygous FLT3-ITD mutation and is FLT3 dependent, and RS4;11 which expresses wild-type FLT3 with IC50 values of 1.1 nM and 4.2 nM, respectively. AC220 is the most potent cellular FLT3-ITD inhibitor, leading to the most significant inhibition of MV4-11 cell proliferation with IC50 of 0.56 nM compared to all other FLT3 inhibitors whose IC50 values range from 0.87 nM to 64 nM. AC220 has no inhibitory activity against the proliferation of A375 cells which harbor an activating mutation in BRAF and are not FLT3 dependent, indicating a large window between FLT3 inhibition and general cytotoxic effects. [1]
In vivo Oral administration of AC220 (10 mg/kg) induces time-dependent inhibition of FLT3 autophosphorylation in the FLT3-ITD–dependent MV4-11 tumor xenograft mouse model; the inhibition being 90% at 2 hours and 40% at 24 hours. AC220 significantly extends survival in a mouse model of FLT3-ITD AML with doses as low as 1 mg/kg given orally once a day. Treatment with AC220 at 10 mg/kg for 28 days results in rapid and complete regression of tumors in all mice with no tumor regrowth during the 60-day posttreatment period. AC220 displays more significant efficacy compared to sunitinib treatment which causes tumors to shrink slowly and resume growth immediately upon discontinuation of treatment in all but one of the mice. [1]
Features The most potent cellular FLT3-ITD inhibitor.

Protocol(Only for Reference)

Kinase Assay: [1]

Inhibition of FLT3 autophosphorylation To measure inhibition of FLT3 autophosphorylation, MV4-11 or RS4;11 cells are cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells are incubated with different concentrations of AC220 for 2 hours at 37 °C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand is added for 15 minutes after the 2-hour AC220 incubation. Cell lysates are prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody. The coated plates are incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody is used for electrochemiluminescence detection on the Meso Scale Discovery platform. The concentration of AC220 that inhibits FLT3-ITD or TLT3-WT autophosphorylation by 50% represents IC50 value

Cell Assay: [1]

Cell lines MV4-11 and RS4;11 cells
Concentrations Dissolved in DMSO, final concentration ~20 μM
Incubation Time 72 hours
Method Cells are cultured overnight in low serum media (0.5% FBS), seeded in a 96-well plate at 40 000 cells per well and exposed to AC220 for 72 hours at 37 °C. Cell viability is measured using the Cell Titer-Blue Cell Viability Assa

Animal Study: [1]

Animal Models Female NU/NU or severe combined immunodeficient mice implanted with MV4-11 cells
Dosages ~10 mg/kg
Administration Oral gavage
Solubility 15% Captisol, 30 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00462761 Completed Acute Myeloid Leukemia|Leukemia|Myelodysplastic Syndrome|AML|MDS Ambit Biosciences Corporation 2007-01 Phase 1
NCT01390337 Recruiting Leukemia, Myeloid, Acute Astellas Pharma Inc|Ambit Biosciences Corporation 2011-10 Phase 1
NCT01468467 Recruiting Leukemia, Myeloid, Acute, Astellas Pharma Inc|Ambit Biosciences Corporation 2012-04 Phase 1
NCT01565668 Active, not recruiting Leukemia, Myeloid, Acute Astellas Pharma Inc|Astellas Pharma Global Development, Inc.|Ambit Biosciences Corporation 2012-04 Phase 2

Chemical Information

Download Quizartinib (AC220) SDF
Molecular Weight (MW) 560.67
Formula

C29H32N6O4S

CAS No. 950769-58-1
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A
Solubility (25°C) * In vitro DMSO 33.2 mg/mL (59 mM)
Water <0.3 mg/mL
Ethanol <0.5 mg/mL
In vivo 15% Captisol, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]-

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.56067 5.6067 11.2134 16.8201

Research Area

Customer Reviews (1)


Click to enlarge
Rating
Source Quizartinib (AC220) purchased from Selleck
Method MTT Assay
Cell Lines epidermoid carcinoma cell line
Concentrations 0.75-3 μM
Incubation Time
Results Effect of AC220 on the sensitivity of KB-C2 cells to paclitaxel.

Product Citations (5)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related FLT3 Inhibitors

  • TCS 359

    TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM.

    Features:Highly potent and selective.

  • PRT062607 (P505-15, BIIB057) HCl

    PRT062607 (P505-15) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.

  • PP2

    PP2 is Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • Quizartinib (AC220)

    Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 1/2.

    Features:The most potent cellular FLT3-ITD inhibitor.

  • Dovitinib (TKI-258, CHIR-258)

    Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2. Phase 4.

  • Dovitinib (TKI-258) Dilactic Acid

    Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.

  • Tandutinib (MLN518)

    Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 1/2.

  • KW-2449

    KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFRβ, IGF-1R, EGFR. Phase 1.

    Features:Investigated as a FLT3 inhibitor in clinical trials, with others in early development.

  • ENMD-2076

    ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.

    Features:Multi-target, anti-proliferative, pro-apoptotic activity, anti-angiogenic.

  • ENMD-2076 L-(+)-Tartaric acid

    ENMD-2076 (L-(+)-Tartaric acid) is the tartaric acid of ENMD-2076, selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.

    Features:Multi-functional molecule: multi-target, anti-proliferative, pro-apoptotic activity, and anti-angiogenic activity.

Recently Viewed Items

Tags: buy Quizartinib (AC220) | Quizartinib (AC220) supplier | purchase Quizartinib (AC220) | Quizartinib (AC220) cost | Quizartinib (AC220) manufacturer | order Quizartinib (AC220) | Quizartinib (AC220) distributor
Contact Us